Compare Costco Wholesale Corporation (COST) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Costco Wholesale Corporation vs Novavax Inc — how do they compare? Costco Wholesale Corporation trades at $924.43 (market cap $408.78B), while Novavax Inc trades at $8.28 (market cap $1.38B). The key difference: Costco Wholesale Corporation is far larger — about 296.2× Novavax Inc's market cap, and Costco Wholesale Corporation pays a 0.64% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| COST | NVAX | |
|---|---|---|
Market Cap | $408.78B | $1.38B |
Sector | Consumer Staples | Health |
52-Week High | $1.09K | $11.19 |
52-Week Low | $849.63 | $6.22 |
Enterprise Value | $396.92B | $889.29M |
Dividend Yield | 0.64% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Costco Wholesale Corporation (COST) trades at $923.76, down 0.29% on the day, as technical indicators signal a bearish trend with the price near pivot point support. Fundamentally, the company shows consistent revenue growth, reaching $275.24B in 2025, and strong cash flow generation of $13.34B from operations, though valuation metrics like a P/E of 46.37 appear elevated. Recent news highlights a March sales surge of 11.3% year-over-year and the first membership fee increase in seven years, which analysts view positively for future profit growth.
The investment outlook balances strong business fundamentals against a high valuation and near-term technical weakness. Upside potential is supported by robust membership renewal rates, expanding margins, and a consensus price target of $1,120. Key risks include sensitivity to consumer spending, competitive pressures in retail, and the stock's premium valuation requiring sustained execution to justify further gains.
Novavax (NVAX) trades at $8.91, down 4.5% today, with a bearish technical signal despite recent earnings beats. The company shows mixed fundamentals with strong revenue of $1.12B in 2025 but negative equity of -$623.84M. Analyst consensus remains bullish with a $14.00 price target, though cash flow trends show ongoing operational losses. Recent news highlights shareholder dissent and market underperformance compared to peers.
The outlook is cautious; while valuation ratios like P/E of 3.14 appear attractive, persistent negative cash flow and high liabilities pose significant risks. Upside depends on sustainable profitability and execution amid competitive vaccine markets. Investors should weigh analyst optimism against fundamental weaknesses and volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Costco Wholesale Corporation
The leading warehouse club, Costco has 815 stores worldwide (at the end of fiscal 2021), with most sales derived in the United States (72%) and Canada (14%). It sells memberships that allow customers to shop in its warehouses, which feature low prices on a limited product assortment. Costco mainly caters to individual shoppers, but roughly 20% of paid members carry business memberships. Food and sundries accounted for 40% of fiscal 2021 sales, with non-food merchandise 29%, warehouse ancillary and other businesses (such as fuel and pharmacy) nearly 17%, and fresh food 14%. Costco's warehouses average around 146,000 square feet
Read more on COST →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
